Bone Other Current Assets vs Capital Stock Analysis

BBLGW Stock

USD 60.50 0.00 0.00%

Bone Biologics financial indicator trend analysis is way more than just evaluating Bone Biologics Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bone Biologics Corp is a good investment. Please check the relationship between Bone Biologics Other Current Assets and its Capital Stock accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

Other Current Assets vs Capital Stock

Other Current Assets vs Capital Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bone Biologics Corp Other Current Assets account and Capital Stock. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Bone Biologics' Other Current Assets and Capital Stock is -0.65. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Capital Stock in the same time period over historical financial statements of Bone Biologics Corp, assuming nothing else is changed. The correlation between historical values of Bone Biologics' Other Current Assets and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of Bone Biologics Corp are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Other Current Assets i.e., Bone Biologics' Other Current Assets and Capital Stock go up and down completely randomly.

Correlation Coefficient

-0.65

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Capital Stock

The total amount of a company's capital funded by shareholders through the issue and subscription of shares.

Most indicators from Bone Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bone Biologics Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

At this time, Bone Biologics' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to climb to 0.20 in 2024, whereas Selling General Administrative is likely to drop slightly above 2 M in 2024.

	2022	2023	2024 (projected)
Tax Provision	3.2K	3.7K	2.1K
Interest Expense	2.2M	2.0M	1.5M

Tax Provision Interest Expense

Bone Biologics fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Net Debt	Cash	Cash And Short Term Investments	Total Current Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Other Stockholder Equity	Total Liab	Common Stock	Short Long Term Debt Total	Other Current Assets	Short Term Debt	Accounts Payable	Net Receivables	Non Current Liabilities Total	Inventory	Current Deferred Revenue	Long Term Debt	Net Invested Capital	Net Working Capital	Short Long Term Debt	Capital Stock
Common Stock Shares Outstanding		-0.39	-0.21	-0.36	-0.42	-0.39	-0.49	-0.34	0.24	0.67	-0.63	-0.51	-0.56	-0.74	-0.39	-0.37	-0.2	-0.61	-0.08	0.7	-0.52	-0.44	-0.23	0.03	-0.37	0.21
Total Assets	-0.39		-0.65	0.99	0.76	1.0	0.65	-0.11	0.62	-0.45	0.59	-0.25	-0.07	0.55	0.67	-0.31	-0.27	0.35	-0.57	-0.33	0.38	0.44	0.9	0.61	0.49	-0.58
Net Debt	-0.21	-0.65		-0.68	-0.34	-0.66	-0.18	0.56	-0.99	-0.02	-0.12	0.89	0.73	0.08	-0.43	0.82	0.34	0.21	0.81	-0.21	0.01	-0.15	-0.8	-0.78	-0.28	0.7
Cash	-0.36	0.99	-0.68		0.78	0.99	0.66	-0.12	0.64	-0.47	0.62	-0.29	-0.11	0.55	0.7	-0.29	-0.29	0.4	-0.57	-0.34	0.43	0.48	0.94	0.61	0.51	-0.59
Cash And Short Term Investments	-0.42	0.76	-0.34	0.78		0.76	0.71	0.39	0.28	-0.57	0.66	0.04	0.05	0.66	0.92	0.06	0.19	0.55	-0.16	-0.44	0.55	0.59	0.64	0.08	0.64	-0.38
Total Current Assets	-0.39	1.0	-0.66	0.99	0.76		0.65	-0.11	0.62	-0.45	0.59	-0.25	-0.07	0.55	0.67	-0.31	-0.27	0.35	-0.57	-0.33	0.38	0.44	0.9	0.61	0.49	-0.58
Other Current Liab	-0.49	0.65	-0.18	0.66	0.71	0.65		0.21	0.08	-0.52	0.6	0.22	0.41	0.57	0.6	0.03	0.02	0.59	-0.02	-0.71	0.34	0.31	0.56	0.2	0.34	-0.17
Total Current Liabilities	-0.34	-0.11	0.56	-0.12	0.39	-0.11	0.21		-0.6	-0.32	0.24	0.68	0.46	0.38	0.28	0.62	0.52	0.42	0.31	-0.36	0.3	0.31	-0.31	-0.84	0.07	0.3
Total Stockholder Equity	0.24	0.62	-0.99	0.64	0.28	0.62	0.08	-0.6		0.07	0.06	-0.92	-0.77	-0.13	0.37	-0.83	-0.36	-0.27	-0.82	0.29	-0.05	0.12	0.77	0.78	0.25	-0.7
Retained Earnings	0.67	-0.45	-0.02	-0.47	-0.57	-0.45	-0.52	-0.32	0.07		-0.96	-0.35	-0.33	-0.93	-0.71	-0.37	-0.3	-0.87	0.05	0.88	-0.91	-0.83	-0.46	-0.02	-0.76	0.53
Other Stockholder Equity	-0.63	0.59	-0.12	0.62	0.66	0.59	0.6	0.24	0.06	-0.96		0.23	0.26	0.93	0.74	0.28	0.22	0.86	-0.14	-0.84	0.91	0.86	0.61	0.14	0.79	-0.54
Total Liab	-0.51	-0.25	0.89	-0.29	0.04	-0.25	0.22	0.68	-0.92	-0.35	0.23		0.91	0.45	-0.09	0.86	0.32	0.52	0.72	-0.54	0.27	0.09	-0.49	-0.65	-0.04	0.53
Common Stock	-0.56	-0.07	0.73	-0.11	0.05	-0.07	0.41	0.46	-0.77	-0.33	0.26	0.91		0.43	-0.12	0.7	0.18	0.53	0.6	-0.61	0.21	-0.08	-0.3	-0.38	-0.17	0.48
Short Long Term Debt Total	-0.74	0.55	0.08	0.55	0.66	0.55	0.57	0.38	-0.13	-0.93	0.93	0.45	0.43		0.69	0.42	0.29	0.82	0.03	-0.82	0.84	0.81	0.44	0.01	0.76	-0.42
Other Current Assets	-0.39	0.67	-0.43	0.7	0.92	0.67	0.6	0.28	0.37	-0.71	0.74	-0.09	-0.12	0.69		-0.05	0.33	0.55	-0.25	-0.5	0.65	0.72	0.66	0.15	0.8	-0.65
Short Term Debt	-0.37	-0.31	0.82	-0.29	0.06	-0.31	0.03	0.62	-0.83	-0.37	0.28	0.86	0.7	0.42	-0.05		0.21	0.63	0.69	-0.43	0.49	0.24	-0.42	-0.68	0.06	0.52
Accounts Payable	-0.2	-0.27	0.34	-0.29	0.19	-0.27	0.02	0.52	-0.36	-0.3	0.22	0.32	0.18	0.29	0.33	0.21		0.12	0.33	-0.26	0.22	0.23	-0.33	-0.53	0.3	-0.13
Net Receivables	-0.61	0.35	0.21	0.4	0.55	0.35	0.59	0.42	-0.27	-0.87	0.86	0.52	0.53	0.82	0.55	0.63	0.12		0.17	-0.88	0.89	0.68	0.35	-0.14	0.53	-0.14
Non Current Liabilities Total	-0.08	-0.57	0.81	-0.57	-0.16	-0.57	-0.02	0.31	-0.82	0.05	-0.14	0.72	0.6	0.03	-0.25	0.69	0.33	0.17		-0.14	-0.03	-0.21	-0.69	-0.55	-0.1	0.69
Inventory	0.7	-0.33	-0.21	-0.34	-0.44	-0.33	-0.71	-0.36	0.29	0.88	-0.84	-0.54	-0.61	-0.82	-0.5	-0.43	-0.26	-0.88	-0.14		-0.73	-0.59	-0.31	0.06	-0.5	0.25
Current Deferred Revenue	-0.52	0.38	0.01	0.43	0.55	0.38	0.34	0.3	-0.05	-0.91	0.91	0.27	0.21	0.84	0.65	0.49	0.22	0.89	-0.03	-0.73		0.86	0.44	-0.05	0.75	-0.42
Long Term Debt	-0.44	0.44	-0.15	0.48	0.59	0.44	0.31	0.31	0.12	-0.83	0.86	0.09	-0.08	0.81	0.72	0.24	0.23	0.68	-0.21	-0.59	0.86		0.51	-0.01	0.89	-0.57
Net Invested Capital	-0.23	0.9	-0.8	0.94	0.64	0.9	0.56	-0.31	0.77	-0.46	0.61	-0.49	-0.3	0.44	0.66	-0.42	-0.33	0.35	-0.69	-0.31	0.44	0.51		0.71	0.54	-0.71
Net Working Capital	0.03	0.61	-0.78	0.61	0.08	0.61	0.2	-0.84	0.78	-0.02	0.14	-0.65	-0.38	0.01	0.15	-0.68	-0.53	-0.14	-0.55	0.06	-0.05	-0.01	0.71		0.2	-0.58
Short Long Term Debt	-0.37	0.49	-0.28	0.51	0.64	0.49	0.34	0.07	0.25	-0.76	0.79	-0.04	-0.17	0.76	0.8	0.06	0.3	0.53	-0.1	-0.5	0.75	0.89	0.54	0.2		-0.66
Capital Stock	0.21	-0.58	0.7	-0.59	-0.38	-0.58	-0.17	0.3	-0.7	0.53	-0.54	0.53	0.48	-0.42	-0.65	0.52	-0.13	-0.14	0.69	0.25	-0.42	-0.57	-0.71	-0.58	-0.66

Click cells to compare fundamentals

Bone Biologics Account Relationship Matchups

Bone Biologics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	12.2K	12.1K	18.9K	47.6K	263.1K	250.0K
Total Assets	30.8K	0.0	6.7M	8.5M	3.7M	2.3M
Net Debt	11.3M	11.7M	(6.7M)	(7.5M)	(3.0M)	(2.9M)
Cash	24.1K	0.0	6.7M	7.5M	3.0M	2.0M
Cash And Short Term Investments	955.4K	24.1K	6.7M	7.5M	3.0M	2.1M
Liabilities And Stockholders Equity	30.8K	13.7M	6.7M	8.5M	3.7M	3.5M
Total Current Assets	30.8K	0.0	6.7M	8.5M	3.7M	2.3M
Other Current Liab	513.7K	535.6K	1.5M	2.5M	470.7K	447.2K
Total Current Liabilities	578.4K	13.7M	99.9K	2.5M	831.4K	789.8K
Total Stockholder Equity	(11.9M)	(13.7M)	6.6M	5.9M	2.9M	3.1M
Retained Earnings	(67.0M)	(68.9M)	(70.5M)	(72.0M)	(80.9M)	(76.9M)
Total Liab	11.9M	13.7M	99.9K	2.5M	831.4K	789.8K
Short Long Term Debt Total	8.2M	9M	11.3M	11.7M	13.5M	8.3M
Other Current Assets	105.2K	85.3K	6.7K	956.9K	711.2K	746.8K
Accounts Payable	42.9K	465.4K	99.9K	888.46	360.7K	202.9K
Non Current Liabilities Total	11.3M	12.2M	99.9K	888.46	799.61	759.63
Net Invested Capital	(547.6K)	(2.0M)	6.6M	5.9M	2.9M	2.1M
Net Working Capital	(547.6K)	(13.7M)	6.6M	5.9M	2.9M	3.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

S	SentinelOne
MSFT	Microsoft
MSFT	Microsoft

Additional Tools for Bone Stock Analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bone Other Current Assets vs Capital Stock Analysis

Other Current Assets vs Capital Stock

Other Current Assets vs Capital Stock Correlation Analysis

Correlation Coefficient

Other Current Assets

Capital Stock

Bone Biologics fundamental ratios Correlations

Bone Biologics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bone Biologics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Bone Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash
Net Invested Capital	+ 0.94	Cash
Short Long Term Debt Total	+ 0.93	Other Stockholder Equity
Other Current Assets	+ 0.92	Cash And Short Term Investments

Total Stockholder Equity	- 0.99	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Short Long Term Debt Total	- 0.93	Retained Earnings
Total Liab	- 0.92	Total Stockholder Equity
Current Deferred Revenue	- 0.91	Retained Earnings
Inventory	- 0.88	Net Receivables